CliffBio
small molecule

PREGABALIN

PREGABALIN

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand namePREGABALIN
Active ingredientPREGABALIN
Strength150MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2020
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

PREGABALIN patent cliff — loss of exclusivity — | CliffBio